Peer-Reviewed Study Confirms CADScor System Can Diagnose Heart Failure With Far Fewer False Positives Than Standard Blood Test

Acarix-backed peer-reviewed research found its investigational SCG heart-failure algorithms delivered 92.9% AUC for HFrEF detection versus 94.7% for NT-proBNP, while improving specificity to 92.0% from 68.8% and more than doubling positive predictive value to 57.7% from 27.1%. The study also classified 71 of 139 (51%) ultimately non-HF referrals as minimal risk, suggesting potential to reduce unnecessary echocardiograms. The opportunity expands CADScor beyond its current CAD indication, but the heart-failure algorithm remains exploratory, requires larger external validation, and is not FDA-approved.

Analysis

The publication creates option value for ACARIX rather than near-term revenue: an additional clinical use case could raise system utilization and improve distributor economics, but the algorithm cannot be marketed for heart-failure triage until a validation program and FDA clearance are completed. The study’s enriched design, small sample, and company funding make the reported precision insufficient to underwrite reimbursement or adoption assumptions. Near-term share-price strength would likely be liquidity-driven given the First North/OTCQB listing structure, making any move vulnerable to financing concerns before a pivotal study is funded.

The economic prize is not direct displacement of NT-proBNP; it is reducing low-value echocardiography referrals and shortening primary-care triage. If externally replicated, this positions ACARIX as a workflow complement to imaging rather than a threat to large diagnostics franchises such as Roche (ROG.SW) or Abbott (ABT), whose biomarker menus and installed-base relationships remain entrenched. The more relevant competitive risk is that GE HealthCare (GEHC), Philips (PHG), and handheld-ultrasound vendors can defend referral pathways with integrated imaging and AI tools; ACARIX needs evidence that its device changes clinician behavior and generates reimbursable savings.

Over the next 1-3 months, monitor management disclosure of validation-trial design, enrollment sites, FDA pathway, cash runway, and U.S. commercial placements. Over 6-18 months, external-validation performance—especially specificity across obesity, atrial fibrillation, renal dysfunction, and preserved-EF populations—will determine whether the theoretical reduction in downstream testing becomes credible. The contrarian view is that investors may capitalize a large heart-failure TAM prematurely: without coverage, prospective outcomes data, and sales-force capacity, an expanded indication could add R&D burn well before it adds recurring consumables revenue.

Key Decisions for Investors

• No core position in ACARIX/ACIXF on this release alone; treat as a watchlist catalyst. Reassess only after a funded, prospectively defined external-validation trial is announced with a credible FDA submission timeline.
• For existing ACARIX holders, use any event-driven rally to reduce exposure unless management demonstrates at least 18-24 months of cash runway after the required validation spend; dilution risk is the principal 6-12 month downside.
• Set an alert for prospective validation showing HFrEF specificity near or above 85% while maintaining sensitivity, plus disclosed U.S. reimbursement or health-system pilot data. Failure to replicate performance across independent centers falsifies the incremental-indication thesis.
• Avoid shorting ABT, ROG.SW, GEHC, or PHG on this development: ACARIX is not yet commercially authorized in heart failure and, if successful, is more likely to expand front-end testing volumes than meaningfully cannibalize incumbent diagnostic revenue.